CTLA4 and pachyonychia congenita: Although studies with RT combination with anti-PD-L1/PD-1 MoAbs are not available, radiotherapy increased by 2–3-fold the overall survival rates of patients with metastatic PC undergoing ipilimumab (anti-CTLA4 MoAb) immunotherapy [21].